Tobalina et al. reported a meta-analysis including 327 BRCA1/BRCA2 mutant patients with ovarian cancer, breast cancer, pancreatic cancer or prostate cancer, who progressed on platinum-based or PARP inhibitor treatment. The gene discussed is BRCA2; the disease is prostate cancer.